Waleed S Alharbi
Overview
Explore the profile of Waleed S Alharbi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
172
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alharbi W, Alshehri A, Ahmed T, Shadab M, Almehmady A, Alshabibi M, et al.
Curr Pharm Des
. 2024 Mar;
30(14):1075-1084.
PMID: 38532602
Background: Due to its volatility, photostability, and gastrointestinal toxicity, Perillyl Alcohol (POH), a monoterpenoid component of various plant species, is a chemotherapeutic drug with insufficient efficacy. Many naturally occurring bioactive...
2.
Ahmed T, Almehmady A, Alharbi W, Alshehri A, Almughem F, Altamimi R, et al.
Biomedicines
. 2023 Oct;
11(10).
PMID: 37893144
Perillyl alcohol (PA), a naturally existing monocyclic terpene related to limonene, is characterized by its poor aqueous solubility and very limited bioavailability. Its potential anti-cancer activity against malignant glioma has...
3.
El-Say K, Alamri S, Alsulimani H, Alharbi W, Omar A, Safo M, et al.
Int J Pharm
. 2023 Apr;
639:122966.
PMID: 37084835
Valsartan (VST) is a poorly soluble antihypertensive drug characterized by its limited dissolution rate and low bioavailability. This study aims to improve VST solubility and dissolution rate via developing liquisolid...
4.
Sindi A, Rizg W, Khan M, Alkhalidi H, Alharbi W, Sabei F, et al.
Drug Deliv
. 2023 Jan;
30(1):2173337.
PMID: 36708105
The use of essential oil-based nanoemulsions (NEs) has been the subject of extensive research on a variety of conditions affecting the oral cavity. NEs are delivery methods that improve the...
5.
Zaineb T, Uzair B, Rizg W, Alharbi W, Alkhalidi H, Hosny K, et al.
Pharmaceutics
. 2022 Dec;
14(12).
PMID: 36559258
It is important to create new generations of materials that can destroy multidrug-resistant bacterial strains, which are a serious public health concern. This study focused on the biosynthesis of an...
6.
Alharbi W, Hareeri R, Bazuhair M, Alfaleh M, Alhakamy N, Fahmy U, et al.
Pharmaceutics
. 2022 Dec;
14(12).
PMID: 36559120
Flibanserin was licensed by the United States Food and Drug Administration (FDA) as an oral non-hormonal therapy for pre-menopausal women with inhibited sexual desire disorder. However, it suffers from susceptibility...
7.
Prakash P, Barwary N, Weber M, Wan D, Conejeros I, Pereira Moreira B, et al.
Diagnostics (Basel)
. 2022 Sep;
12(9).
PMID: 36140465
Rat basophilic leukaemia (RBL) cells have been used for decades as a model of high-affinity Immunoglobulin E (IgE) receptor (FcεRI) signalling. Here, we describe the generation and use of huNPY-mRFP,...
8.
Al-Rabia M, Alfaleh M, Asfour H, Alharbi W, El-Moselhy M, Alhakamy N, et al.
Antioxidants (Basel)
. 2022 Aug;
11(8).
PMID: 36009218
The immunosuppressant cyclosporine A (CSA) has been linked to serious renal toxic effects. Although 2-methoxyestradiol (2ME) possesses a wide range of pharmacological abilities, it suffers poor bioavailability after oral administration....
9.
Ahmed O, Badr-Eldin S, Caruso G, Fahmy U, Alharbi W, Almehmady A, et al.
J Pharm Sci
. 2022 Aug;
111(12):3304-3317.
PMID: 36007556
Preclinical studies suggest that most of statins or 3‑hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors possess pleiotropic anticancer activity. The aim of the present work was to investigate the conjugation of the...
10.
Hosny K, Naveen N, Kurakula M, Sindi A, Sabei F, Al Fatease A, et al.
Gels
. 2022 Jun;
8(6).
PMID: 35735729
Drug administration to the wound site is a potential method for wound healing. The drug retention duration should be extended, and drug permeability through the buccal mucosal layer should be...